Ortho-ATI® Update

Orthocell (ASX $OCC) has today released an update on its Ortho-ATI™ rotator cuff tendon study – the database is now locked and the Company is track to report the highly anticipated top line results in Q4 this calendar year.

This study was designed to assess the effectiveness of Ortho-ATI™, compared to corticosteroids, as a non-surgical treatment for a complex, hard-to-treat clinical problem.

Should the study meet its objectives, Orthocell is well positioned to deliver the first FDA approved injectable cell therapy in orthopaedics for the treatment of chronic tendon injuries in a rotator cuff market estimated at around US$2.8b per annum.

Click here to read today’s ASX release.

Video | Proactive Investors – Orthocell highlights potential for CelGro in treatment of lymphedema

Orthocell CEO and Managing Director Paul Anderson speaks to Proactive after announcing a breakthrough tissue engineering study, combining CelGro™ with lymphatic and blood vessel cells to create functional lymphatic tissue, has been published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Read more